Task V7: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine Candidates

任务 V7：SARS-CoV-2 候选疫苗的临床和 NHP 样本测试

• 批准号: 10329728
• 负责人: THOMAS RUDGE
• 金额: $ 10.66万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-27 至 2022-08-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10329728
• 关键词: 2019-nCoV; Biological; Bioterrorism; COVID-19; COVID-19 testing; COVID-19 vaccine; Clinical; Communicable Diseases; Contracts; Development; Emerging Communicable Diseases; Feasibility Studies; Investigational New Drug Application; Licensing; Sampling; Services; Vaccines; evaluation/testing; novel vaccines; product development; testing services; vaccine candidate; vaccine development

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.

传染病疫苗和其他生物制品的评估和测试服务 (ETS) 合同提供各种产品开发服务，从早期可行性研究到提交生物制品许可申请 (BLA) 和/或研究性新药 (IND) 申请所需的活动。这些服务将促进新候选疫苗和生物制剂（由 CBER 监管）的开发和引进，以对抗潜在的生物恐怖主义和新出现和重新出现的传染病。